8-K: Reviva Pharmaceuticals Provides Enrollment Update for Brilaroxazine Schizophrenia Trial

Reviva Pharmaceuticals announced an enrollment update for its open-label extension study of brilaroxazine in schizophrenia, with 358 patients enrolled and topline data expected in Q4 2024.

Summary

• Reviva Pharmaceuticals has provided an update on the enrollment status of its open-label extension (OLE) study for brilaroxazine, a drug being evaluated for the treatment of schizophrenia.
• As of mid-May 2024, the study has enrolled 358 patients across sites in the USA, Europe, and Asia.
• Currently, 223 patients are actively receiving treatment in the study.
• Over 130 patients have completed between 1 to 6 months of treatment, and over 90 patients have completed 6 to 9 months of treatment.
• 23 patients have completed the full 12 months of treatment.
• The company is on track to complete the 12-month long-term safety study in Q4 2024.
• Long-term safety data from 100 patients who have completed 12 months of treatment is required for the New Drug Application (NDA) submission to the FDA.
• The company expects to submit the NDA to the FDA in Q4 2025.

Sentiment

Score: 7

Explanation: The document presents a positive update on the clinical trial progress, with no significant negative aspects. The trial is progressing as expected, and the company is on track to meet its goals. However, there are inherent risks in drug development, which temper the sentiment.

Positives

• The enrollment for the OLE study is progressing well across multiple regions.
• Brilaroxazine has been generally well tolerated in patients with both acute and stable schizophrenia.
• The company is on track to meet the long-term safety data requirements for the NDA submission.
• The trial is progressing as expected.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to raise sufficient funding is a risk factor.
• There are risks associated with product development, clinical and regulatory timelines, and expenses.

Future Outlook

The company anticipates completing the 12-month long-term safety study in Q4 2024 and submitting an NDA to the FDA in Q4 2025. They also plan to develop brilaroxazine for other neuropsychiatric indications and are exploring its potential in inflammatory diseases.

Management Comments

• Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, stated that they are very pleased with the pace of enrollment of the OLE study.
• He also noted that they are close to gathering long-term safety data in 100 patients with one year of treatment, which is a requirement for their planned NDA submission.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies focused on developing treatments for central nervous system disorders like schizophrenia. The progress of Reviva's brilaroxazine trial is being closely watched by investors and competitors in the CNS space.

Comparison to Industry Standards

• The enrollment numbers and timelines are consistent with other Phase 3 clinical trials for schizophrenia treatments.
• The focus on long-term safety data is a standard requirement for regulatory approval in the pharmaceutical industry.
• The company's stated goal of an NDA submission in Q4 2025 is a typical timeline for a late-stage pharmaceutical company.

Stakeholder Impact

• Shareholders will be encouraged by the positive progress of the clinical trial.
• Patients with schizophrenia may benefit from the potential approval of brilaroxazine.
• The company's employees are working towards the successful completion of the trial and NDA submission.

Next Steps

• The company will continue to monitor the patients in the OLE study.
• They will gather long-term safety data from 100 patients who have completed 12 months of treatment.
• The company will prepare for the NDA submission to the FDA, expected in Q4 2025.
• They will report topline 12 months long-term safety data in the fourth quarter of this year.

Key Dates

Keywords

brilaroxazine, schizophrenia, clinical trial, open-label extension, long-term safety, NDA submission, RECOVER trial, FDA, CNS, pharmaceuticals